NCT00489541CompletedPhase 3
A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
Boston Scientific Corporation54 sites in 1 country224 target enrollmentStarted: July 2007Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 224
- Locations
- 54
- Primary Endpoint
- In-stent Late Loss Measured by Quantitative Coronary Angiography (QCA)
Study Overview
Brief Summary
The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to < 2.75 mm diameter.
Detailed Description
This is a prospective, multi-center, single-arm superiority trial to assess the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the treatment of de novo atherosclerotic lesions of ≤20 mm in length in native coronary arteries with visual RVD of ≥ 2.25 mm to < 2.75 mm diameter.
Two hundred twenty-four (224) subjects will be treated with the TAXUS Element stent at a maximum of 35 clinical sites. Follow-up at 30 days, 9 months including angiography) and 1 year will be completed in all subjects enrolled in the study. Eligible subjects will have annual follow-up until 5 years post-index procedure.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is ≥ 18 years old
- •Eligible for percutaneous coronary intervention (PCI)
- •Documented stable angina pectoris (Canadian Cardiovascular Society [CCS] Classification 1, 2, 3, or 4) or unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia
- •Acceptable candidate for coronary artery bypass grafting (CABG)
- •Left ventricular ejection fraction (LVEF) is ≥ 30%
- •Subject (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
- •Subject willing to comply with all specified follow-up evaluations
Exclusion Criteria
- •Contraindication to aspirin (ASA), or to both clopidogrel and ticlopidine
- •Known hypersensitivity to paclitaxel
- •Known allergy to stainless steel
- •Known allergy to platinum
- •Previous treatment of the target vessel with any anti-restenotic drug-coated or drug-eluting coronary stent
- •Previous treatment of the target vessel with a bare metal stent (BMS) within 9 months of the index procedure
- •Previous treatment of any non-target vessel with any anti-restenotic drug-coated or drug-eluting coronary stent within 9 months of the index procedure
- •Previous treatment with intravascular brachytherapy in the target vessel
- •Planned PCI or CABG post-index procedure
- •Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
- •Myocardial infarction (MI) within 72 hours prior to index procedure
- •Cerebrovascular accident (CVA) within the past 6 months
- •Cardiogenic shock
- •Acute or chronic renal dysfunction
- •Prior anaphylactic reaction to contrast agents
- •Leukopenia
- •Thrombocytopenia
- •Thrombocytosis
- •Active peptic ulcer or active gastrointestinal (GI) bleeding
- •Current treatment, or past-treatment within 12-months of the index procedure, with paclitaxel or other chemotherapeutic agents
- •Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9-months after the index procedure
- •Known intention to procreate within 9 months after the index procedure
- •Positive pregnancy test within 7 days before the index procedure, or lactating
- •Life expectancy of less than 24 months due to other medical conditions
- •Co-morbid condition(s) that could limit subject's ability to comply with study follow-up requirements or impact study scientific integrity
- •Currently participating in another investigational drug or device study
- •Angiographic Inclusion Criteria:
- •Target Lesion
- •Target lesion located in native coronary artery
- •Target lesion must be de novo
- •Target lesion diameter stenosis ≥ 50%
- •Reference vessel diameter (RVD) ≥ 2.25 mm to < 2.75 mm
- •Cumulative target lesion length ≤ 20 mm (area to be treated may be composed of multiple lesions but must be completely coverable by one study stent)
- •Target lesion is successfully pre-dilated
- •One non-target lesion may be treated in a non-target vessel as follows:
- •Non-target lesion in non-target vessel must be treated with commercially available TAXUS stent if use of drug eluting stent required
- •Treatment must be deemed a clinical angiographic success, without requiring use of unplanned additional stents(s)
- •Treatment must be completed prior to treatment of target vessel
- •Angiographic Exclusion Criteria:
- •Target lesion located in left main artery, whether protected or unprotected
- •Target lesion is a chronic total occlusion (TIMI flow ≤ 1)
- •Target lesion is restenotic
- •Target lesion is located in a saphenous vein graft or mammary artery graft
- •Target lesion is accessed via saphenous vein graft or mammary artery graft
- •Target lesion is < 5 mm from bare metal stent (BMS)
- •Target lesion < 5 mm from ostium
- •Target lesion < 5 mm from side branch vessel ≥ 2.0 mm in diameter (Exceptions: subject may be enrolled if side branch is 100% occluded or if side branch is protected with a patent graft)
- •Untreated lesions with ≥ 50% diameter stenosis or thought to impair flow remaining in target vessel at a location with ≥ 2.0mm RVD
- •Target lesion and/or target vessel proximal to target lesion moderately severely calcified
- •Target lesion and/or target vessel proximal to target lesion severely tortuous
- +4 more not shown
Arms & Interventions
TAXUS Element Stent System
Experimental
Intervention: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation (Device)
Outcomes
Primary Outcomes
In-stent Late Loss Measured by Quantitative Coronary Angiography (QCA)
Time Frame: 9 months post-index procedure
Post-procedure minimum lumen diameter (mm) minus follow-up minimum lumen diameter as determined by quantitative angiography. Minimum lumen diameter is measured within the stent at each time point.
Secondary Outcomes
- Number of Participants With Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.(12 months post-index procedure)
Investigators
Study Sites (54)
Loading locations...
Similar Trials
Unknown
Not Applicable
Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) StudyIn-Stent RestenosisCoronary Artery DiseaseNCT04079192Biosensors Europe SA201
Completed
Not Applicable
A Prospective, Non-randomized Study to Evaluate the Safety and Performance of the NovaCross™ Microcatheter in Femoropopliteal Chronic Total Occlusion (CTO).Chronic Total OcclusionNCT02358629Nitiloop Ltd.14
Completed
Not Applicable
Safety and Performance of a GLOBAL Mapping and Ablation Device for the Treatment of Atrial Fibrillation (GLOBAL-AF)Atrial FibrillationNCT02168972Kardium Inc.60
Completed
Not Applicable
To Study the safety and effectiveness of Laser Treatment in Glaucoma patientsCTRI/2017/03/008071Aleyegn Technologies LLC5
Recruiting
Not Applicable
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05189639Pfizer165